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Introduction: Antifungal agents are routinely used in the post-transplant setting for both prophylaxis and
treatment of presumed and proven fungal infections. Micafungin is an echinocandin-class antifungal with broad
antifungal cover and favorable side eﬀect proﬁle but, notably, it has no activity against molds of the order
Mucorales.
Presentation of case: A 47-year-old woman underwent multivisceral transplantation for intestinal failure-asso-
ciated liver disease. She had a prolonged post-operative recovery complicated by invasive candidiasis and de-
veloped an intolerance to liposomal amphotericin B. In view of her immunosuppression, she was commenced on
micafungin as prophylaxis to prevent invasive fungal infection. However, she developed acute graft versus host
disease with bone marrow failure complicated by disseminated mucormycosis which was only diagnosed post
mortem.
Discussion: Non-Aspergillus breakthrough mold infections with micafungin therapy are rare with only eight other
cases having been described in the literature. Breakthrough infections have occurred within one week of starting
micafungin. Diagnosis is problematic and requires a high degree of clinical suspicion and microscopic/histo-
logical examination of an involved site. The management of these aggressive infections involves extensive
debridement and appropriate antifungal cover.
Conclusion: A high level of suspicion of invasive fungal infection is required at all times in immunosuppressed
patients, even those receiving antifungal prophylaxis. Early biopsy is required. Even with early recognition and
aggressive treatment of these infections, prognosis is poor.
Introduction
Solid organ transplant recipients are at risk of opportunistic bac-
terial, viral, parasitic and fungal infections. Broad spectrum anti-
microbial agents are often used for prophylaxis and treatment of op-
portunistic infections post-transplant.
Micafungin is a broad spectrum echinocandin class antifungal agent.
Echinocandins uniquely target the fungal cell wall, giving them a fa-
vorable side eﬀect proﬁle. Micafungin has potent in vitro and in vivo
activity against all major Candida species, Aspergillus species and less
common pathogens such as Paecilomyces and Penicillium. However, it
has no activity against Cryptococcus spp. and members of the order
Mucorales.
Breakthrough infections are a recognized complication of therapy
with any antimicrobial agent, but are an uncommon feature of mica-
fungin use. Here we present a case and review the literature of all
breakthrough non-Aspergillus mold infections described with the use of
micafungin.
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Case
A 47-year-old woman with cirrhosis due to intestinal failure asso-
ciated liver disease was referred for multivisceral transplantation.
Multiple small bowel resections due to visceral myopathy resulted in
short bowel syndrome, small intestinal bacterial overgrowth and gas-
trointestinal dysmotility. A liver biopsy after four years of parenteral
nutrition conﬁrmed advanced cirrhosis and multivisceral transplanta-
tion (stomach, liver, pancreas, small bowel and colon) was indicated.
Both donor and recipient were cytomegalovirus (CMV) IgG nega-
tive. Induction immunosuppression consisted of methylprednisolone
followed by alemtuzumab (anti-CD52). Maintenance immunosuppres-
sion initially consisted of a reducing course of prednisolone and ta-
crolimus. Tacrolimus was replaced by cyclosporine on day 40 due to
posterior reversible encephalopathy syndrome.
Initial recipient antimicrobial prophylaxis consisted of meropenem,
vancomycin, liposomal amphotericin B (L-AmB) 1mg/kg od, co-tri-
moxazole 480mg three times a week and acyclovir, as per our in-
stitutional protocol. On day 3 Candida glabrata was isolated from blood
cultures and drain ﬂuid. The dose of L-AmB was increased to 3mg/kg/
day. This was switched to voriconazole after she developed a cutaneous
drug reaction.
Through her admission there was a prolonged period of pyrexia and
intermittent bacteremia. Positive blood cultures included enterococci,
Elizabethkingia meningoseptica, Staphylococcus haemolyticus, and
Escherichia coli, but there was no fungemia. Voriconazole was switched
to micafungin 100mg od due to low serum voriconazole levels (sec-
ondary to drug interactions) on day 96, which was subsequently in-
creased to 100mg bd due to lack of clinical response.
On day 79 a diﬀuse maculopapular rash was noted. Skin biopsy
demonstrated graft-versus-host disease (GvHD), conﬁrmed by ﬂuores-
cence in situ hybridization analysis. Peripheral blood chimerism ana-
lysis demonstrated 96% donor-positive lymphocytes. She suﬀered from
rapid and irreversible bone marrow failure from day 90 which required
frequent red cell and platelet transfusions. Bone marrow examination
was acellular, consistent with GvHD. Immunosuppression was initially
increased with further doses of high-dose methylprednisolone, basilix-
imab (anti-IL-2), and alemtuzumab with no response.
Immunosuppression was withdrawn on day 120, again with no re-
sponse. A haplo-identical bone marrow transplant from a relative was
planned for day 168.
A granulocyte infusion was given as bridging therapy to control the
sepsis pending bone marrow transplant on day 164 which was asso-
ciated with a platelet increment to> 130×109/L. She was also noted
to have developed dysarthria with unilateral isolated upper motor
neurone facial nerve palsy prior to the infusion. Cranial computed to-
mography scan (CT) (performed after the granulocyte infusion) con-
ﬁrmed an acute frontal infarct. Over the next 24 h she deteriorated
rapidly and was transferred to the intensive care unit. Repeat CT of
head, chest, abdomen and pelvis (Fig. 1) revealed extensive and cata-
strophic infarcts involving both kidneys, bowel and liver, a large new
cerebral infarct, and extension of her established cerebral infarct with
hemorrhagic transformation and signiﬁcant edema and midline shift.
Treatment was withdrawn and she died soon after.
Post mortem examination revealed extensive invasive mucormycosis
diagnosed histopathologically, aﬀecting the vasculature as well as
parenchyma of her lungs, brain, heart and liver, and a left ventricular
fungal thrombus. Following discontinuation of L-AmB and vor-
iconazole, she received micafungin for a total of 69 days. There had
been no time without antifungal coverage. Apart from the early Candida
isolates, fungal cultures and serum galactomannan levels had been
negative throughout her illness.
Methods
PubMed was searched using the search string ‘(micafungin AND
Aspergillus breakthrough [Title/Abstract]) OR (micafungin AND rhi-
zopus [Title/Abstract]) OR (micafungin AND zygomycetes) OR ‘(mi-
cafungin AND Mucor [Title/Abstract]) OR (micafungin AND Rhizopus
[Title/Abstract]) OR (micafungin AND Absidia [Title/Abstract]) OR
(Cunninghamella AND micafungin [Title/Abstract]) OR (Rhizomucor
AND micafungin [Title/Abstract]) OR (Lichtheimia AND micafungin
[Title/Abstract]) OR (Apophysomyces AND micafungin [Title/
Abstract]) OR (Basidiobolus AND micafungin [Title/Abstract]) OR
(Conidiobolus AND micafungin [Title/Abstract])’, OR (Scedosporium
AND micafungin [Title/Abstract]) OR (Fusarium AND micafungin
[Title/Abstract]) and the articles cited therein in articles written in
English for the period January 1997 to December 2017.
Three authors (DE, CM & JLA) then read the articles and included
all clinical cases of breakthrough infection with molds whilst the
Fig. 1. A. CT abdomen at day 165 showing poor enhancement of the liver with
heterogeneous attenuation of the right lobe, gas in the left renal vein (long
arrow) and infarcts in the right kidney (short arrow). B. CT head at day 165
showing extensive bilateral cerebral infarction (long arrows), left fronto-par-
ietal hemorrhage (short arrow) and mass eﬀect within the left cerebral hemi-
sphere.
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patient was receiving micafungin.
Discussion
Invasive fungal infections are known to occur in over 10% of in-
testinal transplant recipients in recent series [1]. In solid organ trans-
plant recipients in general, the majority of fungal infections are due to
Candida or Aspergillus [1], for which both amphotericin B and mica-
fungin provide adequate coverage. In this case micafungin was chosen
to provide prophylaxis while she was neutropenic, due to her intoler-
ance to amphotericin B and interactions with voriconazole, though this
is not a licensed indication [2]. It is likely that Mucor was selected by
micafungin use.
Mucor is a genus of opportunistic environmental molds which
classically causes angioinvasive infections in immunocompromised
patients. Mucormycosis is frequently fatal even with prompt diagnosis,
appropriate therapy and aggressive debridement [3]. Diagnosis requires
a high degree of clinical suspicion and often requires histopathological
examination and culture of involved tissue, as routine cultures are often
negative [3]. Amphotericin B has the best evidence base, although
isavuconazole and posaconazole are alternatives [4,5]. Although
monotherapy is not a therapeutic option, micafungin may be con-
sidered as add-on therapy due to synergistic properties [6]. Micafungin
has limited in vitro activity [i.e. minimum inhibitory concentration
[MIC]>4mg/L] against the mucoraceous molds, Fusarium solani,
Pseudallescheria boydii and molds with holoblastic conidia (e.g. Aur-
eobasidium spp. and Alternaria spp.) [7]. Susceptibility data should
therefore ideally be obtained before starting therapy [8].
Breakthrough infections due to non-Aspergillus molds on mica-
fungin remain rare (Table 1), with only nine other cases previously
reported [9–14]. Other than three case reports, six cases were identiﬁed
during the course of clinical trials involving almost 700 neutropenic
patients receiving micafungin for treatment [10] or prophylaxis [9,14].
Of the eight patients for whom information is available, seven were
receiving immunosuppressive therapy; the other was diabetic. Exposure
to micafungin varied from 6 days to> 3 months. Conversely, several
large multicenter studies of patients receiving micafungin have been
published, predominantly from Japan which showed no breakthrough
infections due to these molds [15–20].
Positive fungal culture or histology remains the gold standard for
diagnosis. Serological markers [e.g. β-D glucan/galactomannan] are
often negative even in overwhelming infection [12]. One of the re-
cognized limitations of β-D glucan is that it remains negative in patients
with infections due to mucormycetes and Cryptococcus [2], whilst ga-
lactomannan, a constituent of the cell wall of Aspergillus and Penicillium
should also remain negative as it’s not a component of these fungi.
Clinical features were non-speciﬁc in all cases and were catastrophic in
ours.
In conclusion, non-Aspergillus non-Candida breakthrough infections
can occur within two weeks of starting micafungin and usually occur in
immunocompromised hosts. A high clinical index of suspicion is re-
quired due to a non-speciﬁc presentation. Clinicians should be aware of
the limitations of antifungal use generally and the limitations of current
screening and diagnostic testing algorithms for detecting fungal infec-
tions in immunosuppressed individuals. Early biopsy is therefore the
most useful investigation in these patients. Unfortunately, even with
prompt recognition and aggressive surgical and antimicrobial therapy,
these infections are often fatal.
Contributions
JR Louis-Auguste: Concept and design of the paper; performed lit-
erature search; drafted and revised the manuscript.
C Micallef: Concept and design of the paper; performed literature
search; drafted and revised the manuscript.
T Ambrose: Concept and design of the paper; revised the Ta
bl
e
1
M
ol
d
br
ea
kt
hr
ou
gh
ca
se
s
du
ri
ng
m
ic
af
un
gi
n
th
er
ap
y
[o
th
er
th
an
A
sp
er
gi
llu
s
sp
p.
].
R
ef
.
Y
ea
r
C
ou
nt
ry
n
O
rg
an
is
m
M
et
ho
d
of
id
en
ti
ﬁ
ca
ti
on
A
ge
/s
ex
U
nd
er
ly
in
g
co
nd
it
io
n
BD
G
Im
m
un
o-
su
pp
re
ss
io
n
Si
te
of
in
fe
ct
io
n
D
ai
ly
do
se
[m
g]
D
ur
at
io
n
of
th
er
ap
y
[t
ot
al
do
se
]
O
ut
co
m
e
Th
is
ca
se
20
14
U
K
1
M
uc
or
m
yc
et
es
H
is
to
lo
gy
–
po
st
m
or
te
m
47
/F
M
V
T,
G
vH
D
,v
is
ce
ra
l
m
yo
pa
th
y
N
/A
M
M
F,
C
Y
A
,s
te
ro
id
s
lu
ng
,b
ra
in
,h
ea
rt
,l
iv
er
10
0–
20
0
69
d
[1
05
00
m
g]
D
ie
d
[1
2]
20
09
Ja
pa
n
1
M
uc
or
m
yc
et
es
H
is
to
lo
gy
–
po
st
m
or
te
m
69
/M
A
M
L,
D
M
N
eg
D
A
,P
re
dn
is
ol
on
e
bo
w
el
15
0
13
d
[1
95
0
m
g]
D
ie
d
[9
]
20
04
U
SA
1
M
uc
or
m
yc
et
es
u/
k
u/
k
H
SC
T
u/
k
u/
k
u/
k
50
u/
k
u/
k
[1
0]
20
10
U
SA
1
M
uc
or
m
yc
et
es
u/
k
u/
k
Fe
br
ile
ne
ut
ro
pe
ni
a
u/
k
u/
k
u/
k
10
0
u/
k
u/
k
[1
4]
20
15
A
us
tr
ia
1
M
uc
or
m
yc
et
es
u/
k
u/
k
A
cu
te
le
uk
em
ia
u/
k
u/
k
lu
ng
50
16
d
[8
00
m
g]
u/
k
[1
4]
20
15
A
us
tr
ia
1
Li
ch
th
ei
m
ia
co
ry
m
bi
fe
ra
H
is
to
lo
gy
–
po
st
m
or
te
m
u/
k
A
cu
te
le
uk
em
ia
u/
k
u/
k
Lu
ng
,
sk
in
,b
ra
in
50
6d
[3
00
m
g]
D
ie
d
[1
4]
20
15
A
us
tr
ia
1
A
ur
eo
ba
si
di
um
sp
p.
u/
k
u/
k
A
cu
te
le
uk
em
ia
u/
k
u/
k
So
ft
ti
ss
ue
50
24
d
[1
20
0
m
g]
u/
k
[1
4]
20
15
A
us
tr
ia
1
H
or
m
og
ra
ph
ie
lla
as
pe
rg
ill
at
a
u/
k
u/
k
A
cu
te
le
uk
em
ia
u/
k
u/
k
Lu
ng
,
sk
in
50
30
d
[1
50
0
m
g]
u/
k
[1
1]
20
13
Ja
pa
n
1
Sc
ed
os
po
ri
um
au
ra
nt
ia
cu
m
C
ul
tu
re
68
/F
D
M
Po
s
N
il
lu
ng
,b
ra
in
15
0
16
d
[2
40
0
m
g]
Su
rv
iv
ed
[1
3]
20
14
Ja
pa
n
1
Sc
ed
os
po
ri
um
pr
ol
iﬁ
ca
ns
C
ul
tu
re
35
/M
R
en
al
tr
an
sp
la
nt
Po
s
M
M
F,
st
er
oi
ds
,
Ta
c
lu
ng
,b
ra
in
,h
ea
rt
va
lv
e,
bl
oo
d
15
0
>
3
m
on
th
s
D
ie
d
K
ey
:A
M
L:
ac
ut
e
m
ye
lo
id
le
uk
em
ia
;B
D
G
:β
-D
-g
lu
ca
n;
C
Y
A
:c
yc
lo
sp
or
in
e;
d:
da
ys
;D
A
:c
yt
ar
ab
in
e
–
da
un
ar
ub
ic
in
;D
M
:d
ia
be
te
s
m
el
lit
us
;F
:f
em
al
e;
G
vH
D
:g
ra
ft
ve
rs
us
ho
st
di
se
as
e;
H
SC
T:
he
m
op
oi
et
ic
st
em
ce
ll
tr
an
sp
la
nt
;
M
:m
al
e;
M
M
F:
m
yc
op
he
no
la
te
m
of
et
il;
M
V
T:
m
ul
ti
vi
sc
er
al
tr
an
sp
la
nt
;
N
/A
:n
ot
ap
pl
ic
ab
le
;N
eg
:n
eg
at
iv
e;
Po
s:
po
si
ti
ve
;T
ac
:T
ac
ro
lim
us
;u
/k
:
un
kn
ow
n;
U
K
:U
ni
te
d
K
in
gd
om
U
SA
:U
ni
te
d
St
at
es
of
A
m
er
ic
a.
J.R. Louis-Auguste et al. IDCases 12 (2018) 76–79
78
manuscript.
S Upponi: Revised the manuscript; provided and interpreted radi-
ological images.
AJ Butler: Concept and design of the paper; revised the manuscript.
D Massey: Concept and design of the paper; revised the manuscript.
SJ Middleton: Concept and design of the paper; revised the manu-
script.
N Russell: Concept and design of the paper; revised the manuscript.
CS Rutter: Concept and design of the paper; revised the manuscript.
LM Sharkey: Concept and design of the paper; revised the manu-
script.
J Woodward: Concept and design of the paper; revised the manu-
script.
E Gkrania-Klotsas: Concept and design of the paper; revised the
manuscript.
DA Enoch: Concept and design of the paper; performed literature
search; drafted and revised the manuscript.
Consent
Written informed consent was obtained from the patient’s next of
kin for publication of this case report and accompanying images. A copy
of the written consent is available for review by the Editor-in-Chief of
this journal on request.
Conﬂict of interest statement
DAE has received funding to attend conferences from MSD, Gilead
and Astellas. CR has received funding from Norgine, Shire and Astellas
to attend scientiﬁc conferences; Dr Falk and Shire for invited pre-
sentations; Nutricia for sponsorship of local educational courses. All
other authors declare no conﬂicts of interest.
Funding
None.
Acknowledgement
None.
References
[1] Primeggia J, Matsumoto CS, Fishbein TM, Karacki PS, Fredette TM, Timpone JG.
Infection among adult small bowel and multivisceral transplant recipients in the 30-
day postoperative period. Transpl Infect Dis 2013;15(5):441–8. http://dx.doi.org/
10.1111/tid.12107.
[2] Enoch DA, Idris S, Micallef C, Sule O, Karas J. Micafungin for the treatment of
invasive aspergillosis. J Infect 2014;68(6):507–26.
[3] Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the
clinical manifestations, diagnosis and treatment. Clin Microbiol Infect
2004;10:31–47. http://dx.doi.org/10.1111/j.1470-9465.2004.00843.x.
[4] Enoch DA, Aliyu S, Sule O, Lewis S, Karas J. Posaconazole for the treatment of
mucormycosis. Int J Antimicrob Agents 2011;38(6):465–73.
[5] Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson
GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial
and case-control analysis. Lancet Infect Dis 2016(March). http://dx.doi.org/10.
1016/S1473-3099(16)00071-2.
[6] Rodríguez MM, Calvo E, Serena C, Mariné M, Pastor FJ, Guarro J. Eﬀects of double
and triple combinations of antifungal drugs in a murine model of disseminated
infection by Scedosporium proliﬁcans. Antimicrob Agents Chemother
2009;53(5):2153–5. http://dx.doi.org/10.1128/AAC.01477-08.
[7] Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-
Tudela JL. Activity proﬁle in vitro of micafungin against Spanish clinical isolates of
common and emerging species of yeasts and molds. Antimicrob Agents Chemother
2009;53(5):2192–5. http://dx.doi.org/10.1128/AAC.01543-08.
[8] Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH,
et al. Species-speciﬁc antifungal susceptibility patterns of Scedosporium and
Pseudallescheria species. Antimicrob Agents Chemother 2012;56(5):2635–42.
http://dx.doi.org/10.1128/AAC.05910-11.
[9] van Burik J-AH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH,
et al. Micafungin versus ﬂuconazole for prophylaxis against invasive fungal infec-
tions during neutropenia in patients undergoing hematopoietic stem cell trans-
plantation. Clin Infect Dis 2004;39(10):1407–16. http://dx.doi.org/10.1086/
422312.
[10] Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, et al.
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult
patients with persistent febrile neutropenia: a retrospective, observational, se-
quential cohort analysis. Clin Ther 2010;32(4):637–48. http://dx.doi.org/10.1016/
j.clinthera.2010.04.005.
[11] Nakamura Y, Suzuki N, Nakajima Y, Utsumi Y, Murata O, Nagashima H, et al.
Scedosporium aurantiacum brain abscess after near-drowning in a survivor of a
tsunami in Japan. Respir Investig 2013;51(4):207–11. http://dx.doi.org/10.1016/j.
resinv.2013.07.001.
[12] Suzuki K, Sugawara Y, Sekine T, Nakase K, Katayama N. Breakthrough disseminated
zygomycosis induced massive gastrointestinal bleeding in a patient with acute
myeloid leukemia receiving micafungin. J Infect Chemother 2009;15(1):42–5.
http://dx.doi.org/10.1007/s10156-008-0657-5.
[13] Uno K, Kasahara K, Kutsuna S, Katanami Y, Yamamoto Y, Maeda K, et al. Infective
endocarditis and meningitis due to Scedosporium proliﬁcans in a renal transplant
recipient. J Infect Chemother 2014;20(2):131–3. http://dx.doi.org/10.1016/j.jiac.
2013.09.006.
[14] Nachbaur D, Angelova O, Orth-Höller D, Ditlbacher A, Lackner M, Auberger J, et al.
Primary antifungal prophylaxis with micafungin in patients with haematological
malignancies: real-life data from a retrospective single-centre observational study.
Eur J Haematol 2015;94(3):258–64. http://dx.doi.org/10.1111/ejh.12426.
[15] Chan TSY, Hwang Y-Y, Gill H, Cheung WWW, Tse E, Leung AYH, et al. Antifungal
drug usage in haematologic patients during a 4-year period in an Asian university
teaching hospital. Intern Med J 2013;43(5):541–6. http://dx.doi.org/10.1111/imj.
12064.
[16] Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J, Kanemura N, et al. Eﬃcacy and
safety of micafungin for treating febrile neutropenia in hematological malignancies.
Am J Hematol 2010;85(11):872–6. http://dx.doi.org/10.1002/ajh.21858.
[17] Kobayashi R, Suzuki N, Yoshida M, Iizuka S, Suzuki D, Sano H, et al. Eﬃcacy and
safety of micafungin for febrile neutropenia in pediatric patients with hematological
malignancies: a multicenter prospective study. J Pediatr Hematol Oncol
2013;35(7):e276–9. http://dx.doi.org/10.1097/MPH.0b013e318299c6bd.
[18] Vehreschild MJGT, von Bergwelt-Baildon M, Tran L, Shimabukuro-Vornhagen A,
Wisplinghoﬀ H, Bangard C, et al. Feasibility and eﬀectiveness of posaconazole
prophylaxis in combination with micafungin bridging for patients undergoing al-
logeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for
neutropenic patients. Eur J Haematol 2014;93(5):400–6. http://dx.doi.org/10.
1111/ejh.12368.
[19] Yamaguchi M, Kurokawa T, Ishiyama K, Aoki G, Ueda M, Matano S, et al. Eﬃcacy
and safety of micafungin as an empirical therapy for invasive fungal infections in
patients with hematologic disorders: a multicenter, prospective study. Ann Hematol
2011;90(10):1209–17. http://dx.doi.org/10.1007/s00277-011-1277-1.
[20] Chan TSY, Gill H, Hwang Y-Y, Sim J, Tse ACT, Loong F, et al. Breakthrough invasive
fungal diseases during echinocandin treatment in high-risk hospitalized hemato-
logic patients. Ann Hematol 2014;93(3):493–8. http://dx.doi.org/10.1007/s00277-
013-1882-2.
J.R. Louis-Auguste et al. IDCases 12 (2018) 76–79
79
